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Pulmonary mucosa-associated lymphoid tissue (MALT) lymphoma is the most frequently occurring
subtype of primary pulmonary lymphoma. We retrospectively reviewed articles that reported pulmonary
MALT lymphoma in the China National Knowledge Infrastructure, WANFANG database, and VIP database
published between January 1987 and December 2011, and then investigated the clinical characteristics
and outcomes of the patients in these reported articles. A total of 128 pulmonary MALT lymphoma cases
were identiﬁed and 75 cases had complete information. These results can be used as preliminary data for
planning further studies.
Copyright © 2015, Taiwan Society of Geriatric Emergency & Critical Care Medicine. Published by Elsevier
Taiwan LLC. All rights reserved.1. Introduction
Mucosa-associated lymphoid tissue (MALT) lymphoma is a
distinct subtype of low-grade malignant B-cell extranodal non-
Hodgkin lymphoma (NHL)1,2. Pulmonary MALT lymphoma ac-
counts for < 1% of all lymphomas, although it comprises more than
two-thirds of all primary NHL of the lungs3,4. Because there have
been only a few sporadic reports regarding pulmonary MALT
lymphoma, the optimal management strategy is not well deﬁned.
Thus, we reviewed the literature for determining the clinical fea-
tures of pulmonary MALT lymphoma and the therapeutic ap-
proaches used for these patients in China.
2. Methods
For the period from January 1987 to December 2011, patients
with pulmonary MALT lymphoma were identiﬁed in the China
National Knowledge Infrastructure, WANFANG database, and VIP
database. The diagnosis in all cases had been made by the histo-
logical and pathological features of extranodal marginal zonere that they have no conﬂicts
of Gerontology, 87 Xiangya
, Changsha, Hunan, 410008,
en).
tric Emergency & Critical Care Melymphoma (MZL) of MALT type, as classiﬁed by the International
Lymphoma Study Group. Medical records at the time of diagnosis,
treatments, and follow-up were systematically reviewed. Repeated
cases and those with inadequate data were excluded.
3. Results
A total of 128 patients met our inclusion criteria. The treatment
of 104 patients had been described and 75 patients had detailed
follow-up material.
3.1. Clinical features
The patient group 71 males and 57 females and the mean age
was 51.2 years (range: 25e87 years). The male-to-female ratio was
1.25:1. The clinical features are presented in Table 1.
3.2. Diagnostic procedures and pathological diagnoses
Final diagnoses were determined by pathological biopsy5. For all
cases, the diagnosis was made by the pathological biopsy. Patho-
logical tissues were obtained by surgical biopsy for 71 patients
(55.3%), computed tomography (CT)-guided percutaneous lung
biopsy for 43 patients (33.6%), bronchoscopy for 13 patients (10.2%),
thoracoscopy for one case (0.8%), and ultrasound-guided biopsy for
one case (0.8%). CT-guided biopsy and bronchoscopy were both
used for one case.dicine. Published by Elsevier Taiwan LLC. All rights reserved.
Table 1
Clinical signs and symptoms of 128 patients with pulmonary mucosa-associated
lymphoid tissue lymphoma.
Variable N (%)
Asymptomatic work-up 26 (23)
Symptoms
Expectoration 59 (46.1)
Chest distress 27 (21.1)
Chest pain 26 (20.3)
Dry cough 19 (14.8)
Tachypnea 18 (14.1)
Hemoptysis 16 (12.5)
Dyspnea 8 (6.3)
Fever 24 (18.8)
Sweats 2 (1.6)
Lesion characteristics
Nodule or mass 74 (57.8)
Inﬁltrates 56 (43.8)
Patchy 9 (7.0)
Interstitial 4 (3.1)
Speciﬁc change
Air bronchogram 44 (34.4)
Pleural effusion 11 (8.6)
Hilar lymph node enlargement 2 (1.6)
Mediastinal lymph node enlargement 2 (1.6)
Pulmonary MALT lymphoma in China 179All pathological samples showed dense proliferation of small
lymphocytes that had inﬁltrated the lung. Immunohistochemical
staining was done for 74 cases, and all tumor cells were positive for
CD20 or CD79 expression.
3.3. Treatments and outcomes
Treatments were described for 104 patients. Seven patients
were left untreated and 97 patients received various treatment
combinations, including surgery (44.3%), chemotherapy (29.9%),
surgery plus chemotherapy (19.6%), surgery plus radio-
chemotherapy (3.1%), chemotherapy plus radiotherapy (2.1%), and
anti-inﬂammatory therapy (1%). The regimens used for chemo-
therapy were cyclophosphamide, doxorubicin, vincristine, and
prednisone (CHOP), cyclophosphamide, vincristine, and predni-
sone (CVP), rituximab and CHOP (R-CHOP), and R-CVP.
Seventy-ﬁve patients had the detailed follow-up information
(Table 2). The duration of median follow-up was 48 months (range:
from 1 month to 17 years). Of these 75 cases, 68 patients showed
stable disease (without metastasis or improvement), four patients
showed intrapulmonary or lymphatic metastasis, two patients
showed slight improvement, and one patient died.
4. Discussion
According to our retrospective study, the median age of pul-
monary MALT lymphoma was 51.2 years, and there was a maleTable 2
Outcomes for 75 patients at follow-up.
Treatments Outcome Total
Good prognosis Metastasis Improvement Died
Surgery 24 (89) 2 (7) 1 (4) 0 27
Chemotherapy 26 (90) 1 (3) 1 (3) 1 (3) 29
Sur þ Chem 11 (92) 1 (8) 0 0 12
Anti-inﬂammation 3 (100) 0 0 0 3
Untreated 4 (100) 0 0 0 4
Total 68 4 2 1 75
Data are presented as n (%).
Sur þ Chem ¼ surgery combined with chemotherapy.preponderance6e8. With regard to clinical features and radio-
graphic appearances, both were not speciﬁc. The major treatments
used were surgery, chemotherapy, or a combination of both.
Seventy-ﬁve patients had detailed follow-up data, and 90.1% of
them had stable disease.
Previous studies reported that pulmonary MALT lymphoma
occurred most often in patients age 60 years; the sex differences
reported were conﬂicting in these studies. Our current study,
consistent with earlier studies, implied that the clinical and imag-
ing manifestation were both atypical and had numerous similar-
ities with several other diseases, such as lung cancer, tuberculosis,
and pneumonia2,9. The diverse manifestations always led to
misdiagnosis of pulmonary MALT lymphoma. In addition, the
treatment was various and similar to that presented in other
studies. Recently, researchers reported anti-inﬂammatory treat-
ment with clarithromycin was an effective treatment strategy for
pulmonary MALT lymphomas10,11.
One limitation of the study was the incomplete epidemiological
data and previous medical history. These data would be helpful in
better understanding of the presentation and course of disease12.
We screened 128 cases, and only 75 of them had complete
follow-up data. There are currently no standard treatment pro-
tocols of pulmonary MALT lymphoma. Thus, perfect follow-up data
is needed. Patients’ unwillingness to cooperate and loss of contact
with the physician may be the main reasons for difﬁculty obtaining
a prognosis.
Despite these limitations of the study, the observation and re-
sults of the current study may be suitable for use as an initial
reference for clinicians dealing with pulmonary MALT lymphoma.
In conclusion, the current study conﬁrmed that pulmonary
MALT lymphoma had an indolent behavior and a good prognosis
regardless of medical or surgical treatment. Further clinical studies
with a larger number of patients and complete clinical data are
needed to identify the risk factors and prognostic factors, and
establish treatment guidelines.References
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